These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25264215)

  • 1. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
    Uchida S; Takahashi M; Sugawara M; Saito T; Nakai K; Fujita M; Mochizuki K; Shin I; Morita T; Hikita T; Itakura H; Takahashi Y; Mizuno S; Ohno Y; Ito K; Ito T; Soma M
    J Clin Hypertens (Greenwich); 2014 Oct; 16(10):746-53. PubMed ID: 25264215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K; Ueshima K; Tanaka S; Kosugi S; Sato T; Matsuoka H; Nakao K; Fujita T
    Int J Med Sci; 2013; 10(9):1209-16. PubMed ID: 23935398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
    Masaki M; Mano T; Eguchi A; Fujiwara S; Sugahara M; Hirotani S; Tsujino T; Komamura K; Koshiba M; Masuyama T
    Heart Vessels; 2016 Nov; 31(11):1826-1833. PubMed ID: 26825736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension.
    Hamada T; Yamada K; Mizuta E; Watanabe A; Osaki T; Ishida K; Hasegawa A; Sakata S; Mishima M; Ogino K; Nosaka Y; Miyazaki S; Ohtahara A; Ninomiya H; Kato M; Yoshida A; Taniguchi S; Yamamoto K; Hisatome I
    Clin Exp Hypertens; 2012; 34(7):470-3. PubMed ID: 22681507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
    Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
    Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
    Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
    Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
    Hwang YC; Yoon KH; Cha BS; Lee KW; Jang HC; Min KW; Chung CH; Lee MK
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28840637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.
    Rose GW; Kanno Y; Ikebukuro H; Kaneko M; Kaneko K; Kanno T; Ishida Y; Suzuki H
    Hypertens Res; 2001 Jul; 24(4):377-83. PubMed ID: 11510750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
    Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
    Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes.
    Tanaka M
    J Int Med Res; 2010; 38(2):602-10. PubMed ID: 20515573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy.
    Fujisawa T; Ikegami H; Noso S; Hiromine Y; Kawabata Y; Nishino M; Asano K; Ogihara T
    J Diabetes Complications; 2007; 21(4):252-7. PubMed ID: 17616356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Fukumoto S; Ishimura E; Motoyama K; Morioka T; Kimoto E; Wakikawa K; Shoji S; Koyama H; Shoji T; Emoto M; Nishizawa Y; Inaba M;
    Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
    Shimizu H; Nakagami H; Yasumasa N; Mariana OK; Kyutoku M; Koriyama H; Nakagami F; Shimamura M; Rakugi H; Morishita R
    Hypertens Res; 2012 Jan; 35(1):77-81. PubMed ID: 21881574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model.
    Zhou X; Ono H; Ono Y; Frohlich ED
    J Hypertens; 2002 May; 20(5):993-1000. PubMed ID: 12011661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.